INS and Parkinson disease: A randomised, double-blinded, placebo-controlled trial with 4 weeks of intranasal insulin (INI) application in PD patients improved verbal fluency and Hoehn–Yahr and unified Parkinson’s disease rating scale-part 3 motor scores.